Hosted on MSN1mon
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
The company states: “Datroway, or Dato-DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast ...
BioSpace8d
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
pharmaphorum2d
AZ, Daiichi get FDA nod for Dato-DXd in breast cancer
AstraZeneca and Daiichi Sankyo have claimed ... cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a treatment for previously treated HR+/HER2- breast ...
StockNews14d
3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine
The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...
Seeking Alpha21d
AstraZeneca Post 2024 Earnings: Unwanted Headwinds Warrant Downgrade To Hold
AstraZeneca secured approvals for two new molecular entities. Kavigale received EU approval for the prevention of COVID-19 in immunocompromised people aged 12 years and older. Datroway was ...
Cure Today14d
Datroway May Be Effective in Non-Small Cell Lung Cancer Subtypes
Datroway shows promising antitumor activity in advanced NSCLC with EGFR mutations and ALK rearrangements, achieving a 35.8% overall response rate. The treatment maintains a manageable safety profile, ...